#China #Shanghai #Atopic Dermatitis #Lynk Pharmaceuticals #Zemprocitinib

Lynk Pharmaceuticals Reports Encouraging Phase III Trial Results for Zemprocitinib in Atopic Dermatitis

Lynk Pharmaceuticals Co., Ltd. has recently announced gratifying topline outcomes from its Phase III clinical trial assessing the efficacy of zemprocitinib in patients suffering from moderate-to-severe atopic dermatitis (AD). Conducted as a multicenter, randomized, double-blind, placebo-controlled trial, the study involved 356 participants who were divided to receive either zemprocitinib at dosages of 12 mg or 24 mg, or a placebo.

The trial met all primary and essential secondary endpoints, with significant improvements observed in both treatment groups compared to placebo, reaching a remarkable statistical significance of (p < 0.0001). These results indicate that zemprocitinib merits further exploration as a potential treatment solution for those battling this chronic inflammatory skin condition.

Study Design and Objectives

The Phase III study aimed to evaluate the safety and efficacy of zemprocitinib in alleviating symptoms associated with moderate-to-severe AD. Key endpoints included the proportion of patients achieving a ≥75% improvement in the Eczema Area and Severity Index (EASI-75) and those attaining a validated Investigator Global Assessment score of 0 (clear) or 1 (almost clear) with a ≥2-point improvement from baseline (vIGA-AD 0/1 response). Key secondary endpoints focused on itch relief, evaluated through the Worst Itch Numerical Rating Scale (WI-NRS4).

Primary and Secondary Findings

Initial findings at Week 16 revealed profound differences: the EASI-75 response rates were 38.1% and 46.4% for the 12 mg and 24 mg groups respectively compared to placebo. Similarly, 30.3% of participants on the 12 mg and 31.0% on the 24 mg achieved a vIGA-AD 0/1 response. Significant improvements were also recorded on the WI-NRS4, showcasing a rapid onset of action as patients experienced itch relief as early as Day 1 of treatment.

Further statistical analysis confirmed zemprocitinib’s efficacy across a multitude of secondary endpoints, including EASI-50 and Dermatology Life Quality Index (DLQI) scoring, which correlates with improvements in overall quality of life for patients.

Safety Profile

Importantly, the drug exhibited an acceptable safety profile, with most treatment-emergent adverse events being of Grade 1–2 severity, paralleling placebo levels. Serious adverse events remained low, reinforcing the need for continued evaluation without immediate safety concerns.

Professor Jianzhong Zhang, a key investigator, remarked on the significant burden AD poses on patients’ quality of life, stating, “In this Phase III study, zemprocitinib showcased marked improvements in skin clearing and itch relief, coupled with a favorable safety profile.”

Looking Ahead

Lynk Pharmaceuticals’ Chief Development Officer, Dr. Yu Wu, noted the critical milestone the results represent in supporting the company’s strategic focus in the immunology sector. As they venture towards regulatory submissions, Lynk’s commitment to uphold scientific quality and standards remains steadfast.

The CEO, Dr. Zhao-Kui Wan, expressed gratitude to all involved and underscored the potential for zemprocitinib to offer an innovative oral treatment for those affected by moderate-to-severe AD.

Conclusion

Zemprocitinib, a next-generation JAK1 inhibitor, is also being explored for other conditions including rheumatoid arthritis and vitiligo. Its development continues to reflect Lynk Pharmaceuticals’ dedication to meeting the unmet medical needs in the domain of immune and inflammatory diseases. As future data gets released, it may significantly impact treatment paradigms for atopic dermatitis and beyond.